PALI vs. PSTV, EVAX, APTO, SNTI, IKT, COEP, CLDI, ONVO, TCBP, and CHRO
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Plus Therapeutics (PSTV), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Senti Biosciences (SNTI), Inhibikase Therapeutics (IKT), Coeptis Therapeutics (COEP), Calidi Biotherapeutics (CLDI), Organovo (ONVO), TC Biopharm (TCBP), and Chromocell Therapeutics (CHRO). These companies are all part of the "medical" sector.
Palisade Bio (NASDAQ:PALI) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.
Palisade Bio has higher earnings, but lower revenue than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.
Palisade Bio has a net margin of 0.00% compared to Plus Therapeutics' net margin of -193.49%. Palisade Bio's return on equity of -105.39% beat Plus Therapeutics' return on equity.
11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 3.3% of Palisade Bio shares are owned by company insiders. Comparatively, 2.3% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Palisade Bio presently has a consensus target price of $22.50, indicating a potential upside of 430.66%. Plus Therapeutics has a consensus target price of $8.00, indicating a potential upside of 321.05%. Given Palisade Bio's higher possible upside, analysts clearly believe Palisade Bio is more favorable than Plus Therapeutics.
Plus Therapeutics received 55 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 60.58% of users gave Plus Therapeutics an outperform vote while only 44.44% of users gave Palisade Bio an outperform vote.
In the previous week, Plus Therapeutics had 1 more articles in the media than Palisade Bio. MarketBeat recorded 3 mentions for Plus Therapeutics and 2 mentions for Palisade Bio. Plus Therapeutics' average media sentiment score of 0.62 beat Palisade Bio's score of 0.32 indicating that Plus Therapeutics is being referred to more favorably in the news media.
Palisade Bio has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Plus Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Summary
Palisade Bio beats Plus Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
